Mesoblast Ltd (MESO) SEC filings

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30

$13.27+0.17 (+1.30%)

Close on Nov 13, 2026Market cap $1.72BP/E –Yield –

SEC filings

40 of Mesoblast's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 10, 2026	Nov 12, 2026	SEC EDGAR
Current report	6-K	Nov 2, 2026	Nov 3, 2026	SEC EDGAR
Current report	6-K	Oct 29, 2026	Oct 29, 2026	SEC EDGAR
Current report	6-K	Oct 16, 2026	Oct 16, 2026	SEC EDGAR
Current report	6-K	Oct 14, 2026	Oct 15, 2026	SEC EDGAR
Current report	6-K	Oct 13, 2026	Oct 13, 2026	SEC EDGAR
Current report	6-K	Sep 24, 2026	Sep 24, 2026	SEC EDGAR
Current report	6-K	Aug 27, 2026	Aug 27, 2026	SEC EDGAR
Annual report	20-F	Jun 30, 2026	Aug 27, 2026	SEC EDGAR
Current report	6-K	Aug 25, 2026	Aug 25, 2026	SEC EDGAR
Current report	6-K	Aug 24, 2026	Aug 24, 2026	SEC EDGAR
Current report	6-K	Aug 17, 2026	Aug 18, 2026	SEC EDGAR
Current report	6-K	Jul 30, 2026	Jul 30, 2026	SEC EDGAR
Current report	6-K	Jul 21, 2026	Jul 21, 2026	SEC EDGAR
Current report	6-K	Jul 14, 2026	Jul 15, 2026	SEC EDGAR
Current report	6-K	Jul 14, 2026	Jul 14, 2026	SEC EDGAR
Current report	6-K	Jul 10, 2026	Jul 10, 2026	SEC EDGAR
Current report	6-K	Jul 1, 2026	Jul 1, 2026	SEC EDGAR
Current report	6-K	Jun 25, 2026	Jun 25, 2026	SEC EDGAR
Current report	6-K	Jun 10, 2026	Jun 10, 2026	SEC EDGAR
Current report	6-K	Apr 30, 2026	Apr 30, 2026	SEC EDGAR
Current report	6-K	Apr 29, 2026	Apr 29, 2026	SEC EDGAR
Current report	6-K	Apr 17, 2026	Apr 17, 2026	SEC EDGAR
Current report	6-K	Apr 15, 2026	Apr 15, 2026	SEC EDGAR
Current report	6-K	Apr 8, 2026	Apr 8, 2026	SEC EDGAR
Current report	6-K	Apr 8, 2026	Apr 8, 2026	SEC EDGAR
Current report	6-K	Apr 8, 2026	Apr 8, 2026	SEC EDGAR
Current report	6-K	Apr 8, 2026	Apr 8, 2026	SEC EDGAR
Current report	6-K	Mar 23, 2026	Mar 23, 2026	SEC EDGAR
Current report	6-K	Mar 18, 2026	Mar 18, 2026	SEC EDGAR
Current report	6-K	Mar 12, 2026	Mar 13, 2026	SEC EDGAR
Current report	6-K	Mar 12, 2026	Mar 12, 2026	SEC EDGAR
Current report	6-K	Feb 27, 2026	Feb 27, 2026	SEC EDGAR
Current report	6-K	Dec 31, 2025	Feb 27, 2026	SEC EDGAR
Current report	6-K	Feb 23, 2026	Feb 23, 2026	SEC EDGAR
Current report	6-K	Feb 12, 2026	Feb 12, 2026	SEC EDGAR
Current report	6-K	Jan 29, 2026	Jan 29, 2026	SEC EDGAR
Current report	6-K	Jan 28, 2026	Jan 28, 2026	SEC EDGAR
Current report	6-K	Jan 19, 2026	Jan 21, 2026	SEC EDGAR
Current report	6-K	Jan 16, 2026	Jan 16, 2026	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Mesoblast's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on Jan 10, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MESO.

Compare: MESO vs IPSC · MESO vs AUTL · MESO vs AGEN · MESO vs KYMR · MESO vs RGNX

Revenue growth599.2% · median 79.6%

Gross margin86.1% · median 35.8%

Net margin-47.8% · median -186.4%

Company	Revenue	Growth
RGNX	$174.48M	+12.0%
AUTL	$137.43M	+168.8%
AGEN	$133.95M	+25.4%
MESO	$120.25M	+599.2%
KYMR	$102.24M	+133.8%
IPSC	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: June 30
Employees: 108
Auditor: PricewaterhouseCoopers
SEC CIK: 1345099

Advertisement
300 × 250

See a number that looks wrong?